These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28392539)

  • 1. Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy.
    Watanabe K; Kosaka T; Hongo H; Tamaki S; Oya M
    Keio J Med; 2017 Dec; 66(4):65-71. PubMed ID: 28392539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Case of Choroidal and Brain Metastases from Castration-Resistant Prostate Cancer].
    Yoneyama S; Watanabe T; Onuki T; Yabuki K; Suzuki K
    Hinyokika Kiyo; 2018 Apr; 64(4):181-186. PubMed ID: 29772621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation.
    Di Lorenzo G; Buonerba C; de Placido S
    Anticancer Drugs; 2015 Feb; 26(2):236-9. PubMed ID: 25340916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
    Yanai Y; Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jul; 19(1):720. PubMed ID: 31331293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
    Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
    Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
    Ecstein-Fraisse E; Su Z
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
    Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.
    Hofheinz RD; Lange C; Ecke T; Kloss S; Linsse B; Windemuth-Kieselbach C; Hammerer P; Al-Batran SE
    BJU Int; 2017 May; 119(5):731-740. PubMed ID: 27618249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
    Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
    Zustovich F; Fabiani F
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
    Nozawa M; Mukai H; Takahashi S; Uemura H; Kosaka T; Onozawa Y; Miyazaki J; Suzuki K; Okihara K; Arai Y; Kamba T; Kato M; Nakai Y; Furuse H; Kume H; Ide H; Kitamura H; Yokomizo A; Kimura T; Tomita Y; Ohno K; Kakehi Y
    Int J Clin Oncol; 2015 Oct; 20(5):1026-34. PubMed ID: 25809824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
    Cicero G; De Luca R; Dorangricchia P; Galvano A; Lo Re G; Serretta V; Dispensa N; Dieli F
    Oncology; 2017; 92(2):94-100. PubMed ID: 27960186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel for the treatment of prostate cancer.
    Michielsen DP; Braeckman JG; Denis L
    Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
    Bahl A; Masson S; Malik Z; Birtle AJ; Sundar S; Jones RJ; James ND; Mason MD; Kumar S; Bottomley D; Lydon A; Chowdhury S; Wylie J; de Bono JS
    BJU Int; 2015 Dec; 116(6):880-7. PubMed ID: 25639506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.
    Caffo O; Veccia A; Russo L; Galligioni E
    Future Oncol; 2012 Dec; 8(12):1585-95. PubMed ID: 23231520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.